Early Signals From PD-1 Checkpoint Inhibitors in First-Line NSCLC Early Signals From PD-1 Checkpoint Inhibitors in First-Line NSCLC

Dr Jack West analyzes the most recent data on PD-1 checkpoint inhibitors as first-line non-small cell lung cancer therapy and predicts how these relatively new agents will affect standard treatments.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

In this study, we analyzed the combination of ionizing radiation (IR) along with microRNA-mediated targeting of genes involved in DSB repair to sensitize human non-small cell lung cancer (NSCLC) cells. MicroRNAs are natural occurring modulators of gene expression and therefore represent an attractive strategy to affect the expression of DSB repair genes. As possible IR-sensitizing targets genes we selected genes of homologous recombination (HR) and non-homologous end joining (NHEJ) pathway (i.e. RAD51, BRCA2, PRKDC, XRCC5, LIG1). We examined these genes to determine whether they may be real targets of selected miRNAs by fu...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by array Homo sapiens Source Type: research
Although programmed death (PD) ‐1 immune checkpoint therapies target the immune system, the relationship between inflammatory factors and the clinical outcome of anti‐PD‐1 therapy for nonsmall cell lung cancer (NSCLC) is not fully understood. Here we examined the association between soluble immune mediators and the outcome of treatment with PD‐1 inhibitors in patients with advanced/recurrent NSCLC. In two independent cohorts, we assessed the levels of 88 different soluble immune mediators in peripheral blood before and after anti‐PD‐1 treatment, and evaluated their associations with clinical outcomes. In the tr...
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Cancer Therapy and Prevention Source Type: research
Authors: Ryszawy D, Rolski F, Ryczek K, Catapano J, Wróbel T, Michalik M, Czyż J Abstract Epidemiological data suggests that there are functional links between bronchial asthma and lung carcinogenesis. Bronchial fibroblasts serve a prominent role in the asthmatic process; however, their involvement in lung cancer progression remains unaddressed. To estimate the effect of the asthmatic microenvironment on the invasiveness of lung cancer cells, the present study compared the behavior of human non-small cell lung cancer A549 cells exposed to the signals from human bronchial fibroblasts (HBFs) derived from non-...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In this study, we analyzed the combination of ionizing radiation (IR) along with microRNA-mediated targeting of genes involved in DSB repair to sensitize human non-small cell lung cancer (NSCLC) cells. MicroRNAs are natural occurring modulators of gene expression and therefore represent an attractive strategy to affect the expression of DSB repair genes. As possible IR-sensitizing targets genes we selected genes of homologous recombination (HR) and non-homologous end joining (NHEJ) pathway (i.e. RAD51, BRCA2, PRKDC, XRCC5, LIG1). We examined these genes to determine whether they may be real targets of selected miRNAs by fu...
Source: Biochimica et Biophysica Acta (BBA) Gene Regulatory Mechanisms - Category: Genetics & Stem Cells Source Type: research
ConclusionsThe present study describes the development of an image analytic module for assessing tumor growth rate and the data demonstrates the functionality and reproducibility of the module in a pilot cohort of EGFR-mutant NSCLC patients treated with EGFR-TKI. The image analytic module is an initial step for clinical translation of the tumor growth rate approach to guide cancer treatment in precision oncology.
Source: European Journal of Radiology - Category: Radiology Source Type: research
SummaryNon-small cell lung cancer (NSCLC) treatment was booming at this year ’s ASCO 2018 meeting as several well-performed phase III trials with practice-changing potential were presented. Thereby immune checkpoint blockade (ICB) consolidated its major role in the treatment of NSCLC patients without genetic alterations and extended its use by showing impressive data on I CB combination therapies (mainly combined with chemotherapy). Furthermore the role of predictive biomarkers for ICB therapy (Programmed death-ligand 1 [PD-L1] expression, tumor mutational burden [TMB] testing and others) have been further ...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
The number of elderly people with advanced lung cancer is increasing globally owing to the aging population and advances in cancer therapy [1]. More than 50% of patients diagnosed with lung cancer are aged>65 years, which is the lower limit for defining “elderly” in epidemiologic researches [2]. Non-small-cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer among both the elderly [3] and the adults. Although platinum-combination regimens including newer agents are the standard first-line chemotherapy for most patients with adva nced NSCLC, their use in elderly patients remains controversial [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
ConclusionsThis case series represents the first description of potential skeletal adverse effects related to immune checkpoint inhibitors. These findings are important for providers caring for patients who experience musculoskeletal symptoms and may merit additional evaluation.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Publication date: Available online 3 October 2018Source: Chemico-Biological InteractionsAuthor(s): Pan Jiang, Hai Xu, Chuyue Xu, Aochang Chen, Lijun Chen, Ming Zhou, Ijaz ul Haq, Xiaoyue Wu, Zahula Mariyam, Qing FengAbstractLong non-coding RNAs (lncRNAs) have been identified to exert crucial roles in tumorigenesis and can serve as novel biomarkers for cancer therapy including lung cancer. Cisplatin is a first-line chemotherapeutic agent in non-small cell lung cancer (NSCLC), but the therapeutic effect is unsatisfactory, partly due to drug resistance. Emerging evidence showed that chemo-resistance is associated with acquisi...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Abstract Long non-coding RNAs (lncRNAs) have been identified to exert crucial roles in tumorigenesis and can serve as novel biomarkers for cancer therapy including lung cancer. Cisplatin is a first-line chemotherapeutic agent in non-small cell lung cancer (NSCLC), but the therapeutic effect is unsatisfactory, partly due to drug resistance. Emerging evidence showed that chemo-resistance is associated with acquisition of cancer stem cell (CSC)-like properties. Cisplatin resistance remains a major obstacle in the treatment of lung cancer, and its mechanism is still not fully elucidated. Meanwhile, CSCs have been invo...
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Tags: Chem Biol Interact Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hematology | Lung Cancer | Non-Small Cell Lung Cancer